Protean Research is dedicated to transforming cancer treatment by developing next-generation diagnostics that guide the selection of combination therapies. Our mission is to empower clinicians with the tools they need to determine the most effective, personalized treatments for each patient—ultimately improving outcomes and saving lives.
Cancer is notoriously adaptable. Even when a therapy initially appears effective, many tumors find ways to evade its impact. This drug escape (often synonymous with drug resistance) results in cancer progression and often requires new or additional treatments. As the number of approved oncology drugs grows, understanding and predicting how tumors might outmaneuver each agent becomes increasingly vital.
Over the next few years, many new oncology therapies will reach the market, offering unprecedented options for patients and clinicians. However, with such a rapidly expanding toolkit, clinicians face a daunting challenge: how to identify the most potent drug or combination of drugs for each specific tumor profile. Traditional diagnostic models have not kept pace with this expansion, leaving an urgent need for more sophisticated approaches.
Despite significant advances in analytical techniques—from genomics and proteomics to novel imaging methods—diagnostic innovations in oncology have not kept up. Existing companion diagnostics are typically tied to individual drugs or specific biomarkers, and do not address the broader, cross-cancer need to rationally select among multiple therapies. As a result, patients often miss the optimal therapeutic combination because today’s diagnostics offer only limited guidance.
Evidence shows that pairing patients with the best possible combination of therapies yields the greatest impact on long-term outcomes. Yet, funding and development resources have traditionally flowed toward drug discovery and development rather than diagnostic innovation. Protean Research fills this critical gap by leveraging advanced analytical techniques and data-driven models to match each patient’s cancer profile to the most promising therapy combination.
Whether you are a pharmaceutical company, healthcare provider, or research institution,
we invite you to explore collaboration opportunities with us.
Email: info@proteanresearch.org